A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection | Zendy

Lorna Leal | Zendy; Agathe León | Zendy; Berta Torres | Zendy; Alexy Inciarte | Zendy; Constanza Lucero | Zendy; Josep Mallolas | Zendy; Montserrat Laguno | Zendy; Marı́a Martı́nez-Rebollar | Zendy; Ana González-Cordón | Zendy; Christian Manzardo | Zendy; Jhon Rojas | Zendy; Judit Pich | Zendy; Joan Albert Arnáiz | Zendy; Josep M. Gatell | Zendy; Felipe García | Zendy

Open Access

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection

Author(s) -

Lorna Leal,

Agathe León,

Berta Torres,

Alexy Inciarte,

Constanza Lucero,

Josep Mallolas,

Montserrat Laguno,

Marı́a Martı́nez-Rebollar,

Ana González-Cordón,

Christian Manzardo,

Jhon Rojas,

Judit Pich,

Joan Albert Arnáiz,

Josep M. Gatell,

Felipe García

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw048

Subject(s) - lopinavir , emtricitabine , ritonavir , maraviroc , medicine , lopinavir/ritonavir , randomized controlled trial , adverse effect , clinical endpoint , regimen , viral load , virology , human immunodeficiency virus (hiv) , covid-19 , disease , antiretroviral therapy , infectious disease (medical specialty)

The objective of this study was to assess post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus maraviroc, both with tenofovir disoproxil/emtricitabine as the backbone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research